Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $205.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by equities researchers at Morgan Stanley from $185.00 to $205.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target would suggest a potential upside of 18.71% from the stock’s current price.

Several other research firms also recently commented on JAZZ. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. lowered their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $180.07.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $31.63 during trading hours on Monday, reaching $172.70. 4,353,483 shares of the stock traded hands, compared to its average volume of 910,855. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a 50 day simple moving average of $134.07 and a two-hundred day simple moving average of $120.39. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $172.03. The company has a market cap of $10.49 billion, a price-to-earnings ratio of -25.49, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, beating the consensus estimate of $5.87 by $2.26. The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company earned $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, analysts predict that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Activity

In related news, Director Bruce C. Cozadd sold 3,500 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the transaction, the director owned 408,826 shares in the company, valued at $57,235,640. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 11,500 shares of company stock valued at $1,525,280 over the last quarter. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in shares of Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after acquiring an additional 298,815 shares in the last quarter. Capital World Investors boosted its holdings in Jazz Pharmaceuticals by 0.4% in the third quarter. Capital World Investors now owns 2,554,867 shares of the specialty pharmaceutical company’s stock valued at $336,731,000 after acquiring an additional 10,345 shares in the last quarter. LSV Asset Management increased its position in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after purchasing an additional 87,576 shares during the period. Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.